Trial · NCT00934089
Outcomes30
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 30
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 8 Ante Meridiem (AM) (0 Hour) | 8 AM on Baseline (Day -8), 8 AM on Day 14 (0 Hour) | Per-protocol (PP) population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 10 AM (2 Hours) | 10 AM on Baseline (Day -8), 10 AM on Day 14 (2 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 12 Post Meridiem (PM) (4 Hours) | 12 PM on Baseline (Day -8), 12 PM on Day 14 (4 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 2 PM (6 Hours) | 2 PM on Baseline (Day -8), 2 PM on Day 14 (6 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. Here 'number analyzed' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 4 PM (8 Hours) | 4 PM on Baseline (Day -8), 4 PM on Day 14 (8 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. Here 'number analyzed' signifies those participants who were evaluable for this measure at given time points for each group, respectively. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 6 PM (10 Hours) | 6 PM on Baseline (Day -8), 6 PM on Day 14 (10 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 8 PM (12 Hours) | 8 PM on Baseline (Day -8), 8 PM on Day 14 (12 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 10 PM (14 Hours) | 10 PM on Day -8 (Baseline), 10 PM on Day 14 (14 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 15: 12 AM (16 Hours) | 12 AM on Baseline (Day -7), 12 AM on Day 15 (16 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 15: 4 AM (20 Hours) | 4 AM on Baseline (Day -7), 4 AM on Day 15 (20 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 15: 6 AM (22 Hours) | 6 AM on Baseline (Day -7), 6 AM on Day 15 (22 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 15: 8 AM (24 Hours) | 8 AM on Baseline (Day -7), 8 AM on Day 15 (24 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 16: 8 AM (48 Hours) | 8 AM on Baseline (Day -8), 8 AM on Day 16 (48 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 17: 8 AM (72 Hours) | 8 AM on Baseline (Day -8), 8 AM on Day 17 (72 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. Here 'overall number of participants analyzed) signifies those participants who were evaluable for this outcome measure. | mmHg | MEAN |
| PRIMARY | Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 21: 8 AM (168 Hours) | 8 AM on Day -8 (Baseline), 8 AM on Day 21 (168 Hours) | PP population included all participants who completed the study treatment with no major protocol violations. | mmHg | MEAN |
| PRIMARY | Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 5 Minutes on Day 14 | 5 minutes post-dose on Day 14 | Evaluable PK population included all enrolled participants who completed study treatment, had at least 1 quantifiable concentration (that is, at least 1 concentration above the limit of quantification) and had no major protocol deviation. Here 'overall number of participants analyzed' signifies those participants who were evaluable for this outcome measure. | pg/mL | MEAN |
| PRIMARY | Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 0.25 Hours on Day 14 | 0.25 hours post-dose on Day 14 | Evaluable PK population included all enrolled participants who completed study treatment, had at least 1 quantifiable concentration (that is, at least 1 concentration above the limit of quantification) and had no major protocol deviation. | pg/mL | MEAN |
| PRIMARY | Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 0.5 Hours on Day 14 | 0.5 hours post-dose on Day 14 | Evaluable PK population included all enrolled participants who completed study treatment, had at least 1 quantifiable concentration (that is, at least 1 concentration above the limit of quantification) and had no major protocol deviation. | pg/mL | MEAN |
| PRIMARY | Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 0.75 Hours on Day 14 | 0.75 hours post-dose on Day 14 | Evaluable PK population included all enrolled participants who completed study treatment, had at least 1 quantifiable concentration (that is, at least 1 concentration above the limit of quantification) and had no major protocol deviation. | pg/mL | MEAN |
| PRIMARY | Plasma Concentration for PF-04217329 Active Metabolite (CP-544326) at 1 Hour on Day 14 | 1 hour post-dose on Day 14 | Evaluable PK population included all enrolled participants who completed study treatment, had at least 1 quantifiable concentration (that is, at least 1 concentration above the limit of quantification) and had no major protocol deviation. | pg/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00934089/outcomes